Xin Tong

Title: Innovations of Inventor Xin Tong

Introduction

Xin Tong is a notable inventor based in College Park, MD (US), recognized for his contributions to the field of glycoengineering. With a total of four patents to his name, he has made significant advancements in the synthesis and remodeling of therapeutic antibodies.

Latest Patents

His latest patents include "Endo-S2 mutants as glycosynthases, method of making and use for glycoengineering of glycoproteins." This invention provides recombinant Endo-S2 mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for synthesizing glycoproteins. The invention allows for the addition of a desired sugar chain to a fucosylated or nonfucosylated GlcNAc-IgG acceptor. This innovation enhances biological activities such as prolonged half-life in vivo, reduced immunogenicity, and improved targeting ability. Another significant patent is "Transglycosylation of endo-S and endo-S mutants for antibody glycosylation remodeling." This invention offers a one-pot enzymatic approach that simplifies the process by eliminating the need for enzyme removal and purification of intermediates after the deglycosylation step.

Career Highlights

Xin Tong is affiliated with the University System of Maryland, where he continues to push the boundaries of research in glycoengineering. His work has implications for the development of therapeutic agents that can significantly improve patient outcomes.

Collaborations

He collaborates with esteemed colleagues, including Lai-Xi Wang and Tiezheng Li, who contribute to his research endeavors and innovations.

Conclusion

Xin Tong's work in glycoengineering exemplifies the impact of innovative thinking in the field of biotechnology. His patents not only advance scientific knowledge but also hold the potential to transform therapeutic applications.